Emergency Medical Services Reimbursement for On-Scene and Support Act

The Emergency Medical Services Reimbursement for On-Scene and Support Act (HR7277) was introduced in the House of Representatives on January 30, 2026. It was subsequently referred to the Committee on Energy and Commerce and the Committee on Ways and Means on the same day. This bill proposes to amend the Social Security Act to provide Medicare coverage for ambulance services that do not involve transportation, effective January 1, 2026. This legislation does not specify an explicit funding amount. Instead, it modifies the scope of services covered by Medicare, which would lead to increased reimbursement for specific types of ambulance services. The mechanism is a change in Medicare's reimbursement policy, expanding the types of services for which providers can bill. This is an authorization of a new coverage area, with the actual financial impact dependent on the volume of such services and the reimbursement rates set by Medicare. Structural beneficiaries of this potential policy change include companies involved in ambulance services. American Medical Response, part of $EVH, and ambulance services owned by LabCorp ($LH) would see their total addressable market for Medicare services expand. This would allow them to bill for services previously not covered, potentially increasing their revenue. However, the bill is in its early stages, having only been referred to committees, and its passage is not guaranteed. Looking at recent market data, $EVH is currently trading at $2.31, which is near its 52-week low of $2.10. It has experienced a 7-day change of +6.45% but a 30-day change of -32.06%. $LH is trading at $274.46, within its 52-week range of $209.38 to $293.72. $LH has seen a 7-day change of +4.12% and a 30-day change of -0.53%. These price movements do not directly reflect the bill's progress, as the bill is in its initial stages and its impact is speculative at this point. The legislative path ahead involves committee review, potential amendments, and votes in both the House and Senate, followed by presidential assent. There is a related bill, S3730, in the Senate, which is a companion bill. This indicates bipartisan and bicameral interest in the policy, which could increase its chances of eventual passage. However, the bill's early stage means a significant legislative process remains before it could become law.